TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02301559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates exercises with emphasis on pelvic region
Study: NCT03381118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 40 mg IV infusion on D+1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF mobilized HLA-haploidentical donor PBSC
Description: G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
Study: NCT03771339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural analgesia
Description: Continuous Epidural catheter is inserted at the Thoracic 11-T12 level, using Ropivacaine 0.375% 3 mL bolus followed by Ropivacaine 0.2% with rate 6 mL/hour for 24 hours after laparoscopic nephrectomy
Study: NCT01522898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AV nodal ablation
Description: Percutaneous catheter ablation of the AV node.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Ventricular Rate Control
Description: Ventricular Rate Control with target ventricular rate of 90 beats per minute.
Study: NCT03771339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Quadratus Lumborum block
Description: Bilateral anterior Quadratus Lumborum block using Ropivacaine 0.375% 20 mL each injection as postoperative analgesia treatment for 24 hours
Study: NCT03983330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (i-BMI)
Description: The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
Study: NCT04379674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACILITATION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACILITATION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FACILITATION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INHIBITION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INHIBITION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
Study: NCT03308565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, Adipose derived Mesenchymal Stem Cells
Description: The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
Study: NCT03977350

Intervention type: DEVICE
Intervention: EEG monitoring
Description: EEG monitoring under general anesthesia
Study: NCT04379674

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INHIBITION TAPING
Description: The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO TAPING
Description: Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO TAPING
Description: Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO TAPING
Description: Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
Study: NCT02978664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air insufflation during colonoscopy including insertion phase

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water immersion
Description: Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
Study: NCT02947633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection sciatic PNB
Description: Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous sciatic PNB
Description: Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief.
Study: NCT04258865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study: NCT02911220

Intervention type: GENETIC
Group type: OTHER
Intervention: demonstration of genetic mutations causing non-atopic asthma
Description: recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
Study: NCT05155423

Intervention type: OTHER
Intervention: mask for immobilization
Description: mask for immobilization

Intervention type: OTHER
Intervention: Elekta BodyFix
Description: Elekta BodyFix
Study: NCT02685397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
Study: NCT04023942

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintenance intervention
Description: Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintenance intervention
Description: Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintenance intervention
Description: Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintenance intervention
Description: Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
Study: NCT01461525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection
Description: After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphincter preservation surgery
Description: After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
Study: NCT02300246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin
Description: Alveolar socket preservation with Platelet-Rich Plasma
Study: NCT01319890

Intervention type: PROCEDURE
Intervention: Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)
Description: Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
Study: NCT03787264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o.
Study: NCT00459628

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: Radiation treatment delivered by conventional linear accelerator using matching fields

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
Study: NCT02898883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Resilience after Childhood Emergencies (BRACE)
Description: See arm/group description for details regarding this intervention
Study: NCT01015898

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
Study: NCT01203098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 15mg
Description: DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 30mg
Description: DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium 20 mg (=2000IU)
Description: Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
Study: NCT01417442

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRAF V600E POSITIVITY
Description: BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
Study: NCT02211040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Plan
Description: The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Plan
Description: The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans.
Study: NCT00603616

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching oral placebo pills to be taken twice daily for a total of 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
Study: NCT03095612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor once weekly oral or twice weekly oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel once every 3 weeks (75 mg/m2 IV)
Study: NCT04102787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac educational program
Description: Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management.
Study: NCT02984111

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin
Study: NCT04351594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biofreeze 4 % Topical Gel
Description: Biofreeze gel with active manufactured ingredient (Menthol 4%)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Biofreeze placebo gel
Description: Biofreeze gel with no active manufactured to have the same look, feel and odour as Biofreeze topical gel.
Study: NCT02984111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin
Study: NCT01902199

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TRAA intervention
Description: The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
Study: NCT04461496

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid revascularization
Description: The first stage is performed femoral-popliteal bypass surgery above the fissure of the knee joint according to conventional technology. Conduit is at the discretion of the operating surgeon. Intraoperatively bolus is administered sol. heparin 5000 IU. The second step is the puncture of the selected CFA with a retrograde installation of the introducer sheath. The iliac segment is recanalized with angioplasty and stent implantation in the affected area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full metall Jacket
Description: The first step is the puncture contralateral CFA with a retrograde installation of the introducer. Intraoperatively bolus is administered sol. heparin 5000 IU. A conductor is placed in the contralateral iliac artery along the conductor. A stent is implanted in the iliac artery lesion. The second stage is the recanalization of the femoral-popliteal segment with angioplasty and stent implantation in the affected area.
Study: NCT04355650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support tool
Description: Adults (aged 18-64 years) who meet DSM-5 diagnostic criteria for non-psychotic unipolar major depressive disorder (MDD) and meet study eligibility criteria will receive 8 weeks of open-label treatment with an SSRI or SNRI antidepressant. Depressive symptoms will be assessed using the subject- and clinician-rated versions of the 16-items QIDS scale (QIDS-SR and QIDS-CR) and the 17-item HAMD at baseline, week 2 (via telephone), week 4, and week 8; with an additional phone contact at week 24. The QIDS scale scores at 2- and 4-weeks will be entered into the AHI-based clinical decision support tool, and the outcome predicted by the tool (e.g., the predicted eventual treatment outcome at 8 weeks) will be recorded. Clinicians and patients will be blinded to the clinical decision support tool prediction of outcome provided at the 2- and 4 weeks.
Study: NCT01902199

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRAA intervention
Description: The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
Study: NCT03266536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Western diet
Description: Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with \< 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.